PRN® Omega-3

Product Description:

THE ONLY FORMULA CLINICALLY PROVEN

PRN^® Omega-3 is the only formula clinically proven in Dry Eye patients that improves both signs and symptoms of Dry Eye.

PRN Physician Recommended Nutriceuticals^® is the leading developer of specialty omega-3 products. Developed and endorsed by medical thought leaders, PRN^® products are supported by clinical evidence and are unmatched in quality and purity.

Information

PDFs

View PDF

Article

Clinical Improvement within Twelve Weeks*

Significant improvement in TEAR OSMOLARITY Reduction of 19.4 mOsm/ L
Significant improvement in TEAR BREAK-UP TIME 3.5 second increase
Significant improvement in MMP-9 67.9% reduction in MMP-9 positivity
Significant improvement in OSDI 50% drop in score

*Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes Alice T. Epitropoulos, MD, et al.

See below for further details on each of these improvements

Significant Improvement in

TEAR OSMOLARITY

Reduction of 19.4 mOsm/ L

At the 6-week follow-up, a significant reduction from baseline was measured in tear film osmolarity in the omega-3 group (−16.8 ± 2.6 mOsm/L) versus control group (−9.0 ± 2.7 mOsm/L, P = 0.042), which further decreased from baseline at 12 weeks in the omega-3 group (−19.4 ± 2.7 mOsm/L) versus control group (−8.3 ± 2.8 mOsm/L, P = 0.004).

Significant Improvement in

TEAR BREAK-UP TIME

3.5 second increase

TBUT showed a significant improvement during the 12 weeks in the omega-3 group. At 6 weeks, there was a trend toward TBUT improvement in the omega-3 group, which was not statistically significant (P = 0.126), but the difference between the groups was significant at the 12-week visit (P = 0.002).

Significant Improvement in

OSDI

50% drop in score

Both groups had similar OSDI symptom scores at baseline. At 12 weeks, OSDI symptom scores in the omega-3 group dropped from 32.4 ± 19.2 to 15.5 ± 11.0 versus 27.1 ± 22.9 to 22.0 ± 19.3 in the control group (P = 0.002).